BMX inhibited tumor-induced neovascularization and suppressed <i>in vivo</i> tumor growth in nude mice.

<p>(A) HCT 116 colorectal cancer cells were mixed with Matrigel and then injected subcutaneously into the right flank of nude mice. After implantation, animals were treated intraperitoneally with vehicle or BMX 20 mg/kg/day for 10 days. Matrigel plugs removed from the mice administered intraperitoneally with vehicle or BMX were shown. (B) The blood vessels in the Matrigel plug were stained with anti-CD31 antibody as described in the “<i>Materials and Methods</i>” section. Images of immunohistochemical staining representative of three independent Matrigel plug with similar results are shown. (C) Hemoglobin levels in the Matrigel plug shown in (A) were quantified. Each column represents the mean ± S.E.M. of six plugs in each group (^*p<0.05 as compared with the vehicle-treated control group, n = 5). (C) Nude mice bearing xenografts of HCT116 colorectal cancer cells were treated intraperitoneally with BMX 20 mg/kg/day for 22 days. The control group received vehicle only. Tumor volumes were calculated as described in the <i>Materials and Methods</i> section. Values represents the mean ± S.E.M. (^*p<0.05 as compared with the vehicle-treated control group, n = 5). (D) After 22 days of treatment as in (C), mice were sacrificed and tumors were dissected and weighted. Each column represents the mean ± S.E.M. (^*p<0.05 as compared with the vehicle-treated control group, n = 5). (E) The body weights of the nude mice were examined within 22 days treatment of vehicle or BMX. Values represent the mean ± S.E.M.